Kornimate/medical-research-clean huggingface dataset:
gamified family-based health exercise intervention to improve adherence to 24-h movement behaviors recommendations in children.

Conditions: Physical Inactivity; Obesity, Childhood; Sedentary Behavior

Summary: physical inactivity is the fourth most important risk factor for mortality worldwide and it contributes to weight gain and obesity. on the contrary, it is established that regular physical activity is a prevention and managerial factor of these non-communicable diseases. therefore, the goal of this study is to design and evaluate the effectiveness of a 12-week physical exercise and lifestyle improvement training program carried out in a family environment, through a web platform, and with "online" supervision. this platform will improve the physical conditioning and adherence to pe in a "family environment", and to promote good development of the child through physical activities and exercises that can be done as a family at home and/or outside.


Eligibility criteria:
inclusion criteria: * participants without any physical or mental disorders that would prevent them from completing the assessments tests or participating in the exercise intervention program * one parent/guardian must answer the questionnaires * informed consent from the participants parent(s)/guardian(s) exclusion criteria: * participants with psychiatric disorders or chronic illness that limits their participation in physical activities * participants who do not comply with the established procedures * participants who do not understand the spanish language

Keywords: lack of physical fitness low levels of basic motor skills
combined pharmacotherapies for alcoholism (naltrexone/ondansetron)

Conditions: Alcoholism

Summary: this study will compare the effectiveness of ondansetron (zofran) and naltrexone (revia) both alone and in combination in treating early onset alcoholics versus late onset alcoholics. all subjects will received standardized cognitive behavioral therapy. followup assessments will be completed at 1, 3, 6, and 9 months after treatment.


Eligibility criteria:
inclusion criteria: * current diagnosis of alcohol dependence. * provide a written informed consent. * must weigh within 30% of their ideal body weight. * patients must weigh at least 89 lbs. and no more than 342 lbs. * good physical health. * currently drinking 14 or more alcohol units per week for women and 21 or more alcohol units per week for men in the last 30 days. * provide evidence of stable residence in the last month prior to enrollment in the study. * no plans to move in the nine months after entering the study. * literate in english and able to read, understand, and complete questionnaires and follow instructions. * willingness to participate in behavioral treatment for alcoholism. exclusion criteria: * current psychiatric disorder other than alcohol or nicotine dependence. * elevated liver enzymes or elevated bilirubin. * severe alcohol withdrawal symptoms which require treatment. * serious medical co-morbidity requiring medical intervention or close supervision. * severe or life-threatening adverse reactions to medications in the past or during this trial. * female patients who are pregnant, lactating, or not adhering to an acceptable form of contraception at any time during the study. * received inpatient or outpatient treatment for alcohol dependence within the last 30 days. * compelled to participate in an alcohol treatment program for alcohol dependence to maintain their liberty. * members of the same household. * tuberculosis. * current treatment with any medications having a potential effect on alcohol consumption and related behaviors or mood. * urine must be free of opiates, cocaine, amphetamines, barbiturates, benzodiazepines, prescription and non-prescription drugs. * pyrexia of unknown origin.
mechanism investigation of selinexor combined with lenalidomide and rituximab in the treatment of diffuse large b-cell lymphoma

Conditions: Lymphoma, Large B-Cell, Diffuse

Summary: this is a retrospective observational study of the therapeutic mechanism and resistance mechanism of the treatment of selinexor combined with lenalidomide and rituximab in diffuse large b-cell lymphoma patients. by detecting the immune cells in peripheral blood and tumor tissues of patients before and after treatment, the key immune cell subsets and immune molecules linked to the action and resistance of the treatment of selinexor combined with lenalidomide and rituximab, so as to provide the basis for the optimization of the treatment or the combination of other immunotherapies.


Eligibility criteria:
inclusion criteria: 1. at least 18 years old. 2. histopathologically confirmed diffuse large b-cell lymphoma according to world health organization (who) classification criteria 2016. 3. there is evidence of relapsed or refractory disease. 4. treatment with selinexor combined with lenalidomide and rituximab. exclusion criteria: * no
developmental endothelial locus-1, platelet count, and soluble p-selectin in overweight and obese subjects

Conditions: Overweight and Obesity

Summary: this observational study aims to detect serum levels of developmental endothelial locus-1 (del-1), platelet count, and soluble p-selectin (sp-sel) in overweight and obese subjects. the main questions it aims to answer are: * is there a difference in serum del-1 levels in overweight and obese subjects compared to normal subjects? * are there any relations between serum del-1 levels, sp-sel, and platelet count in overweight and obese subjects ?


Eligibility criteria:
inclusion criteria: * male patients. * age (18-65) years. * healthy overweight and subjects. exclusion criteria: * patients with cardiovascular diseases. * diabetic patients. * previous history of thrombo-embolic diseases. * patients with hyperthyroidism. * patients with any type of malignancy. * underlying hepatic or renal failure. * major surgery within 60 days.
cancer risk in organ transplant recipients and end-stage renal disease

Conditions: Immunocompromised Host; Organ Transplantation; Cancer

Summary: background: * solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression * end-stage renal disease (esrd), the most common type of end-stage organ disease leading to transplant, is itself linked to increased risk for some cancers * the role of immunosuppression and other factors causing cancer in this setting are not fully understood. objectives: * to characterize cancer risk in transplant recipients and identify risk factors. * to characterize risk for transmission of cancer from organ donors to recipients. * to describe cancer risk in esrd. eligibility: patients are not required for this study. data are gathered from existing databases of esrd patients, organ transplant patients and cancer registries. design: * databases of 1) u.s. transplant recipients, donors and wait list candidates and 2) u.s. esrd patients will be linked to multiple u.s. cancer registries to identify cancers in transplant recipients and esrd patients. * the spectrum of cancer risk in transplant recipients and esrd patients will be evaluated in detail. * the cancer risk in transplant recipients will be examined in relation to whether the donors had cancer. * the proposed cancer risk factors (e.g., underlying medical condition, infection with cancer-causing viruses, immunosuppressive medications) documented in transplant and esrd files will be studied for association with increased risk of particular types of cancer.

solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with substantially elevated cancer risk, largely due to the need to maintain long-term immunosuppression. despite previous research, important research questions remain concerning the role of immunosuppression and other factors in causing cancer in the setting. staff at two federal agencies, the national cancer institute (nci) and the health resources and services administration (hrsa), will link a database containing information on u.s. transplant recipients, wait list candidates, and donors to multiple u.s. cancer registries. these data will be used to conduct research concerning the spectrum of cancer risk in transplant recipients. the data will also be used by hrsa in its public health role overseeing the u.s. solid organ transplant network to maintain and improve safety of organ transplantation.

Eligibility criteria:
* this study will include as subjects all individuals included in the transplant data set. all u.s. solid organ transplant recipients, candidates for transplant, and living related donors. in addition, the study will include all individuals in the u.s. esrd data set.

Keywords: organ transplants immunosuppression cancer end stage renal disease esrd cancer risk
pain response to open label placebo in induced acute pain in healthy male adults

Conditions: Acute Pain

Summary: open label placebo application has been shown to be effective in treatment of chronic pain (low back pain) and disease like the irritable bowel syndrome. data about effects on acute pain are spare. the study investigates the effect of an open-label placebo (substance without a medical active component) application on acute pain, evoked via a artificial pain model in healthy male volunteers. 32 healthy male volunteers are recruited.


Eligibility criteria:
inclusion criteria: * healthy male volunteers (american society of anaesthesiologist's class i or ii) * body mass index between 18 and 25kg/m2 * able to understand the study and the nrs scale * able to give informed consent exclusion criteria: * recreational drug abuse * regularly taking medication potentially interfere with pain sensation (analgesics, antihistamines and calcium and potassium channel blockers) * neuropathy * chronic pain * neuromuscular or psychiatric disease * known or suspected kidney or liver disease

Keywords: placebo
recognition of heart failure with micro electro-mechanical sensors (reflecs)

Conditions: Heart Failure; Pulmonary Hypertension

Summary: the study will test the ability a novel wearable sensor based on a smartphone app (precordior cardiosignal app) in combination with a sensor device (suunto movesense sensor) to non-invasively measure cardiac motion and function.

heart failure (hf) is a syndrome where the heart is unable to pump or fill adequately to meet the circulatory needs of the body. the main purpose of this study is to test the ability a novel wearable sensor based on a smartphone app (precordior cardiosignal app) in combination with a sensor device (suunto movesense sensor) to non-invasively measure cardiac motion and function. the phone and sensor are positioned on the chest and echocardiography is used as a gold standard to assess cardiac mechanics including myocardial strain, cardiac torsion, diastolic filling characteristics, hemodynamics including pressure estimates and stroke volume.

Eligibility criteria:
inclusion criteria: * age ≥ 21 years * able to consent in english and follow study instructions * patients hospitalized or being seen in clinic with heart failure with a diagnosis of hfpef, hfref or ph, as corresponding to each target patient group * control patients may include patients that are hospitalized without heart failure, and cardiology patients without heart failure who are seen in outpatient cardiology, who may have suspected cad and are scheduled for ccta. exclusion criteria: * severe cardiac valvular heart disease * previous prosthetic cardiac valve * pericardial disease including constrictive pericarditis or moderate or large pericardial effusion * mechanical circulatory support (including ecmo, lvads etc). * heart and/or lung transplant recipients * major adverse cardiovascular event or surgery within 6 weeks of planned study enrollment * patients with pacemaker that has over 1% of beats paced * pectus excavatum (severe) * pregnant women * on dialysis * exclude at the clinical discretion of the principal investigators * not possible to acquire echocardiography with sufficient quality
neurocognitive effects of buprenorphine among hiv+ and hiv-opioid users

Conditions: Opioid-related Disorders; Buprenorphine; HIV; Cognition; HIV Infections

Summary: the purpose of this study is to examine how buprenorphine, a form of opioid addiction treatment, changes the ability to think and reason among people addicted to opiates, who are either hiv negative or hiv positive. in addition, blood samples will be stored for hiv+ and hiv- individuals who take buprenorphine to study its effect. this study hypothesizes that the hiv positive participants will demonstrate significant improvement in thinking and reasoning ability at 3 and 6 months compared to baseline, but that their thinking and reasoning ability will still be lower than hiv negative participants. this study also hypothesizes the biomarkers in participants' blood samples will be associated with measures of change in thinking and reasoning ability.


Eligibility criteria:
inclusion criteria: * documented hiv-serostatus * english-speaking * age 18-60 * able to give voluntary, signed informed consent * plan to initiate buprenorphine treatment in the next month. exclusion criteria: * over age 60: participants over the age of 60 will be excluded, as normal age-associated cognitive changes may confound neuropsychological (np) assessment and diagnosis of hiv-related cognitive disorders. * neurologic: history of head injury with loss of consciousness for greater than 12 hours; previous penetrating skull wounds; previous brain surgery; known seizure disorder, or any other non-hiv related cns disorders that might affect neurocognitive functioning (e.g., previous cerebrovascular accident, parkinson's disease, multiple sclerosis, brain tumor). * medical: e.g. collagen vascular disorder (e.g. lupus), oxygen requiring chronic pulmonary disease,, or end stage renal disease requiring dialysis. * psychiatric: lifetime diagnosis of schizophrenia or bipolar disorder. * less than 6 years of education. * acute intoxication due to alcohol or other drugs, as assessed by research staff. * use of buprenorphine in the past month, either prescribed or purchased on the street.
mr imaging and mr spectroscopy of hiv

Conditions: HIV Infections

Summary: the center for disease control and prevention estimates that 1,148,200 americans aged 13 years and older are living with hiv infection, including 207,600 (18.1%) who are unaware of their infection. according to pathological data, central nervous system (cns) involvement is commonly found during the early phase of infection. in vivo proton magnetic resonance spectroscopy studies of hiv-infected humans have demonstrated significant changes of metabolites observed in the brain n-acetylaspartate, creatine, choline, glutamate, glutamine and myo-inositol with varying changes in different brain regions. diffusion tensor imaging (dti) is a novel functional mri technique which can be used to derive quantitative in vivo measurements of region-specific and diffuse brain alterations. dti studies have demonstrated changes of mean diffusivity (md) and fractional anisotropy (fa) in the various parts of brain. diffusion abnormalities involving various regions of brain have also been observed in patients infected with hiv. one dimensional (1d) or two-dimensional (2d) magnetic resonance spectroscopic imaging (mrsi) technique has been used for many years to study the metabolites changes in hiv. mri scan time necessary for the acquisition of high-resolution mrsi data with adequate spatial coverage may be prohibitively long for clinical exams. thus, new imaging and bio-chemical characterization techniques are needed to allow repeated, non-invasive assessment of these processes in vivo. since neuroinflammation is associated with increased brain water, diffusion tensor imaging (dti) is sensitive to changes in white matter (wm) and inflammatory changes associated with hiv infections. even though only single-voxel-based diffusion-weighted mrs has been previously investigated, altered diffusivity of non-water metabolites and its relationship with metabolic disturbance as well as structural and functional abnormalities in hiv has not been investigated. the brain apparent diffusion coefficient (adc) changes of metabolites measured by the novel 3d mrsi technique will be correlated with the adcs and fractional anisotrophy of water recorded by dti and cell count to better understand the role of cns involvement in hiv pathology.

this will be a multicenter prospective study. we will recruit ten (10) healthy participants aged 20 to 30 years to investigate the feasibility and test/retest reliability of the repsi sequence. twenty five (25) hiv+ patients will be recruited from the division of hiv medicine (dr. eric daar) at the los angeles biomedical research institute at harbor-ucla medical center (torrance, ca). hiv+ patients will be transported to the ucla medical center for neuroimaging examination.

Eligibility criteria:
inclusion criteria: * hiv-infected between age of 20 and 65 years * consistently have plasma hiv rna levels \<200 copies/ml for at least the last 12 months on a stable antiretroviral regimen with any changes made only for convenience, safety or simplicity. * able to provide informed consent. exclusion criteria: -hiv negative

Keywords: mr spectroscopy central nervous system
dimethyl fumarate for the treatment of intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: the investigators conduct this study to investigate whether oral administration of dimethyl fumarate, a food and drug administration-approved drug for multiple sclerosis, is safe and effective in alleviating phe and neurologic deficits in patients with ich.


Eligibility criteria:
inclusion criteria: 1. men and nonpregnant women aged 18 years and older 2. a primary supratentorial ich of 5 to 30 ml 3. symptom onset less than 72 hours prior to admission 4. a glasgow coma scale (gcs) score of 6 or greater 5. basal ganglia hemorrhage only exclusion criteria: 1. patients with a gcs score of 3 to 5 2. planned surgical evacuation of a large hematoma (\>30 ml) 3. various degrees of dysphagia,and nausea/vomiting, any of which renders oral administration of fingolimod difficult 4. patients with hematoma expansion 5. secondary ich 6. preexisting disability (modified rankin scale \[mrs\] score \>1) 7. any history of bradycardia or atrioventricular block 8. concomitant use of antineoplastic, immunosuppressive, or immune-modulating therapies 9. macular edema 10. patients with known hypersensitivity to dimethyl fumarate or to any excipient of this product 11. pregnant and lactating women

Keywords: dimethyl fumarate intracerebral hemorrhage(ich) perihematomal edema(phe) neurologic deficit immune modulator
dexmedetomidine versus midazolam added to ketamine in pediatric patients undergoing bone marrow aspiration and biopsy

Conditions: Procedural Sedation and Analgesia During Bone Marrow Aspiration and Biopsy

Summary: group i :the patients will receive midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv). group ii : the patients will receive dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine (iv). the objective of this study to evaluate the clinical effects, adverse effects and recovery time of two different sedative agents (midazolam and dexmedetomidine) combined with ketamine during conscious sedation for child patient with haematological cancer undergoing bma \&biopsy.


Eligibility criteria:
inclusion criteria: * all consecutive children with acute lymphoblastic leukemia undergoing bone marrow aspiration and biopsy. exclusion criteria: * previous sensitization or anaphylactic reaction to dexmedetomidine, ketamine,and midazolam; * evidence of head injury, * raised intracranial or intraocular tension; * use of drugs known to interact with either study agent; * an american society of anesthesiologists (asa) physical status score greater than 2. * also patients with cardiovascular, respiratory, hepatic diseases and epilepsy will be excluded.
assessment of handgrip strength in adults with inflammatory bowel disease

Conditions: Inflammatory Bowel Disease; Nutrition

Summary: inflammatory bowel disease (ibd) is a chronic disease, which causes inflammation of the gut. people with this disease are often poorly nourished. problems caused by poor nutrition such as poor wound healing can be reduced if it is recognised and treated early. when people with ibd attend outpatients clinic with their ibd specialist they are weighed and their bmi calculated to indicate if they are poorly nourished. weight and bmi may not always provide a good assessment of how well nourished a person is because it does not describe the amount of muscle in the body in proportion to fat. a person with a low or decreasing amount of muscle but a normal or high bmi is at risk of nutritional problems. measuring the amount of muscle someone with ibd has in routine practice poses a challenge to clinicians due to time constraints. one-way of measuring the amount of muscle a person has is to measure their muscle strength. this can be measured by recording the strength of a person's handgrip. handgrip strength can be measured using a hand-held device called a dynamometer. this study aims to test whether it is possible to measure the handgrip strength of people with ibd attending outpatient's clinic. it also aims to test how the measure obtained compares with other methods of assessing whether someone is malnourished and their health. people with a diagnosis of ibd who are aged 18 or older and who are scheduled to attend ibd outpatients clinic in one hospital will be asked to take part in the study. their handgrip strength will be measured each time they attend clinic over a nine-month period in addition to other information about their health and nutritional state. this study forms part of a masters in research being undertaken with the university of southampton.


Eligibility criteria:
inclusion criteria: 1. adult participants with a confirmed diagnosis of ibd (≥18 years of age) 2. people deemed to have capacity to consent 3. people able to understand and read english 4. people attending a gastroenterology outpatient clinic appointment exclusion criteria: 1. people physically unable to complete the study procedures 2. any person who is currently participating in another research trial in which the principle investigator is not satisfied to sign a 12-week exemption form. 3. people involved in an interventional study. 4. people who are currently an inpatient